EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s stock price has increased by 10.15% compared to its previous closing price of $9.95. However, the company has seen a 14.76% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Is It Worth Investing in EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Right Now?
The 36-month beta value for EYPT is at 1.75. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EYPT is 59.81M, and currently, shorts hold a 11.27% of that float. The average trading volume for EYPT on July 10, 2025 was 818.67K shares.
EYPT’s Market Performance
The stock of EyePoint Pharmaceuticals Inc (EYPT) has seen a 14.76% increase in the past week, with a 22.60% rise in the past month, and a 137.23% gain in the past quarter. The volatility ratio for the week is 7.65%, and the volatility levels for the past 30 days are at 8.18% for EYPT. The simple moving average for the past 20 days is 16.78% for EYPT’s stock, with a 39.62% simple moving average for the past 200 days.
Analysts’ Opinion of EYPT
Many brokerage firms have already submitted their reports for EYPT stocks, with RBC Capital Mkts repeating the rating for EYPT by listing it as a “Outperform.” The predicted price for EYPT in the upcoming period, according to RBC Capital Mkts is $28 based on the research report published on June 17, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see EYPT reach a price target of $33. The rating they have provided for EYPT stocks is “Buy” according to the report published on January 07th, 2025.
EYPT Trading at 40.75% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.63% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from Zaderej Karen L., who purchase 5,000 shares at the price of $5.99 back on May 19 ’25. After this action, Zaderej Karen L. now owns 36,500 shares of EyePoint Pharmaceuticals Inc, valued at $29,950 using the latest closing price.
Zaderej Karen L., the Director of EyePoint Pharmaceuticals Inc, purchase 5,000 shares at $5.81 during a trade that took place back on May 16 ’25, which means that Zaderej Karen L. is holding 31,500 shares at $29,050 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -2.88 for the present operating margin
- 0.93 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -2.62. The total capital return value is set at -0.5. Equity return is now at value -53.54, with -42.43 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.15. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -11526.43.
Currently, EBITDA for the company is -129.23 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 12.37. The receivables turnover for the company is 126.79for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.85.
Conclusion
In conclusion, EyePoint Pharmaceuticals Inc (EYPT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
